Skip to main content

Table 3 Analyses of risk factors for poor clinical outcomes in all patients (n = 84)

From: Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment

Factors Univariate analysis Multivariate analysis
OR 95%CI P-value OR 95%CI P-value
Age > 50 3.221 1.19, 8.70 0.021 2.859
3.346
0.93, 8.78
1.15, 9.73
0.067
0.027
Male 2.130 0.55, 8.21 0.272
Alcohol intake > 40 g/d 4.059 0.48, 33.94 0.196 4.199
5.219
0.44, 39.73
0.58, 46.68
0.211
0.139
INH + RFP 0.739 0.26, 2.14 0.740
Latency < 1 month 0.506 0.15, 1.70 0.270
Hepatocellular DILI 1.308 0.47, 3.66 0.609
Cirrhosis 7.588 2.57, 22.37 0.000 4.382 1.35, 14.21 0.014
HBV co-infection 7.333 1.58, 34.10 0.011 4.504
8.012
0.84, 24.05
1.66, 38.66
0.078
0.010
  1. Only variables with P < 0.200 in the univariate analysis were included in the multivariate analysis. Adjusted statistical data were shown in italic font if the variable of cirrhosis was discarded due to its correlation with chronic HBV infection
  2. Abbreviations: INH isoniazid, RFP rifampin, DILI drug-induced liver injury, HBV hepatitis B virus